Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Metagenomi in a report issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($1.47) for the year. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi's FY2026 earnings at ($0.76) EPS.
Metagenomi (NASDAQ:MGX - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The firm had revenue of $9.61 million during the quarter, compared to analysts' expectations of $13.18 million. Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. During the same quarter in the prior year, the company posted ($20.05) earnings per share.
Several other equities research analysts have also commented on MGX. HC Wainwright boosted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, December 10th. Wells Fargo & Company lowered their target price on Metagenomi from $25.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday, March 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $14.40.
Check Out Our Latest Analysis on MGX
Metagenomi Stock Down 4.4 %
NASDAQ:MGX traded down $0.07 during mid-day trading on Thursday, reaching $1.42. The company's stock had a trading volume of 155,076 shares, compared to its average volume of 922,759. Metagenomi has a 1 year low of $1.41 and a 1 year high of $10.94. The stock has a fifty day moving average of $2.25 and a 200-day moving average of $2.43. The firm has a market capitalization of $52.90 million and a PE ratio of -0.54.
Institutional Trading of Metagenomi
Hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank purchased a new stake in Metagenomi in the fourth quarter valued at about $1,300,000. Peapod Lane Capital LLC acquired a new stake in Metagenomi in the 4th quarter worth approximately $1,268,000. Geode Capital Management LLC grew its position in Metagenomi by 73.8% during the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock worth $2,121,000 after purchasing an additional 249,390 shares during the last quarter. Northern Trust Corp increased its stake in Metagenomi by 185.6% during the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company's stock valued at $808,000 after purchasing an additional 145,536 shares in the last quarter. Finally, Good Life Advisors LLC purchased a new position in shares of Metagenomi in the fourth quarter worth $451,000.
Metagenomi Company Profile
(
Get Free Report)
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Articles
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.